ArticleESMO open2026
Prognostic impact of pathological complete response and response-adapted outcomes in patients with gastroesophageal adenocarcinoma treated with neoadjuvant or perioperative treatments: a multicentric cohort study.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPathological complete response (pCR) after neoadjuvant therapy is an established prognostic marker in several tumor types, but its significance in gastroesophageal adenocarcinoma (GEA) remains unclear. We investigated the role of pCR as a prognostic factor and as a predictive biomarker for benefit from adjuvant chemotherapy in a large real-world cohort of operable GEA. PATIENTS AND
methodsWe retrospectively analyzed data from 532 patients with histologically confirmed esophageal, gastroesophageal junction, and gastric adenocarcinoma treated with neoadjuvant therapy followed by curative surgery (2012-2024) at two European high-volume centers. Tumor regression was assessed using the Becker classification. Overall survival (OS) and disease-free survival (DFS) were analyzed with Cox regression models and stratified by treatment regimen, tumor site, and pathologically documented response (pathological response; PR).
resultspCR was observed in 13% of patients and was significantly associated with improved OS [hazard ratio (HR) 0.23, 95% confidence interval (CI) 0.13-0.40] and DFS (HR 0.29, 95% CI 0.17-0.47, both P < 0.001) in univariable analysis. In multivariable analysis, pCR remained an independent predictor of OS (HR 0.55, 95% CI 0.33-0.92, P = 0.023) and DFS (HR 0.53, 95% CI 0.32-0.89, P = 0.017) after adjustment for clinicopathological variables. Five-year OS and DFS were more than doubled in patients with pCR versus those without pCR (79% versus 39% and 73% versus 39%, respectively). No survival benefit from adjuvant chemotherapy was observed among patients with pCR. In contrast, those with partial or poor PR (Becker tumor regression grade 1b-3) derived significant benefit from post-operative chemotherapy for both OS and DFS (P < 0.001).
conclusionspCR after neoadjuvant therapy is a robust, independent prognostic marker in GEA and is associated with more than double long-term survival compared with nonresponders. While adjuvant chemotherapy does not appear to improve outcomes in patients achieving pCR, it remains beneficial in those with incomplete/partial or absent PR after neoadjuvant chemotherapy. These findings support a response-adapted approach to perioperative treatment strategies in GEA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.